GB0504103D0 - Novel method - Google Patents

Novel method

Info

Publication number
GB0504103D0
GB0504103D0 GBGB0504103.3A GB0504103A GB0504103D0 GB 0504103 D0 GB0504103 D0 GB 0504103D0 GB 0504103 A GB0504103 A GB 0504103A GB 0504103 D0 GB0504103 D0 GB 0504103D0
Authority
GB
United Kingdom
Prior art keywords
disease
compound
novel method
parkinson
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0504103.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Syngenta Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syngenta Ltd filed Critical Syngenta Ltd
Priority to GBGB0504103.3A priority Critical patent/GB0504103D0/en
Publication of GB0504103D0 publication Critical patent/GB0504103D0/en
Priority to EP06709910A priority patent/EP1853241B1/en
Priority to MX2007010480A priority patent/MX2007010480A/es
Priority to US12/090,645 priority patent/US20090326072A1/en
Priority to RU2007131934/15A priority patent/RU2420272C2/ru
Priority to CA002598517A priority patent/CA2598517A1/en
Priority to AT06709910T priority patent/ATE524171T1/de
Priority to JP2007557572A priority patent/JP2008531665A/ja
Priority to PCT/GB2006/000684 priority patent/WO2006090177A1/en
Priority to PT06709910T priority patent/PT1853241E/pt
Priority to ZA200707486A priority patent/ZA200707486B/xx
Priority to DK06709910.1T priority patent/DK1853241T3/da
Priority to CN2006800133878A priority patent/CN101163466B/zh
Priority to ES06709910T priority patent/ES2374761T3/es
Priority to AU2006217650A priority patent/AU2006217650B2/en
Priority to HK08101077.6A priority patent/HK1110211B/en
Priority to BRPI0609177-6A priority patent/BRPI0609177A2/pt
Priority to IL185410A priority patent/IL185410A0/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
GBGB0504103.3A 2005-02-28 2005-02-28 Novel method Ceased GB0504103D0 (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method
BRPI0609177-6A BRPI0609177A2 (pt) 2005-02-28 2006-02-27 uso de um composto, kit, e, composição farmacêutica
PCT/GB2006/000684 WO2006090177A1 (en) 2005-02-28 2006-02-27 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE
ZA200707486A ZA200707486B (en) 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromenthylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
US12/090,645 US20090326072A1 (en) 2005-02-28 2006-02-27 USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-l,3- CYCLOHEXANEDIONE IN THE TREATMENT OF PARKINSON'S DISEASE
RU2007131934/15A RU2420272C2 (ru) 2005-02-28 2006-02-27 Применение 2-(2-нитро-4-трифторметилбензоил)-1,3-циклогександиона при лечении болезни паркинсона
CA002598517A CA2598517A1 (en) 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
AT06709910T ATE524171T1 (de) 2005-02-28 2006-02-27 Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
JP2007557572A JP2008531665A (ja) 2005-02-28 2006-02-27 パーキンソン病の治療における２−（２−ニトロ−４−トリフルオロメチルベンゾイル）−１，３−シクロヘキサンジオンの使用
EP06709910A EP1853241B1 (en) 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3- cyclohexanedione in the treatment of parkinson's disease
PT06709910T PT1853241E (pt) 2005-02-28 2006-02-27 Utilização de 2-(2-nitro-4-trifluorometilbenzoil)-1,3- ciclohexanodiona no tratamento de doença de parkinson
MX2007010480A MX2007010480A (es) 2005-02-28 2006-02-27 Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexandiona en el tratamiento de la enfermedad de parkinson.
DK06709910.1T DK1853241T3 (da) 2005-02-28 2006-02-27 Anvendelse af 2-(2-nitro-4-trifluormethylbenzoyl)-1,3-cyclohexandion ved behandling af Parkinson's sygdom
CN2006800133878A CN101163466B (zh) 2005-02-28 2006-02-27 2-(2-硝基-4-三氟甲基苯甲酰)-1,3-环己二酮在治疗帕金森病中的用途
ES06709910T ES2374761T3 (es) 2005-02-28 2006-02-27 Uso de 2-(2-nitro-4-trifluorometilbenzoil)-1,3-ciclohexanodiona en el tratamiento de la enfermedad de parkinson.
AU2006217650A AU2006217650B2 (en) 2005-02-28 2006-02-27 Use of 2-(2-Nitro-4-Trifluoromethylbenzoyl)-l,3- Cyclohexanedione in the treatment of Parkinson's disease
HK08101077.6A HK1110211B (en) 2005-02-28 2006-02-27 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1, 3-cyclohexanedione in the treatment of parkinson's disease
IL185410A IL185410A0 (en) 2005-02-28 2007-08-21 Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0504103.3A GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method

Publications (1)

Publication Number Publication Date
GB0504103D0 true GB0504103D0 (en) 2005-04-06

Family

ID=34430351

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0504103.3A Ceased GB0504103D0 (en) 2005-02-28 2005-02-28 Novel method

Country Status (17)

Country Link
US (1) US20090326072A1 (https=)
EP (1) EP1853241B1 (https=)
JP (1) JP2008531665A (https=)
CN (1) CN101163466B (https=)
AT (1) ATE524171T1 (https=)
AU (1) AU2006217650B2 (https=)
BR (1) BRPI0609177A2 (https=)
CA (1) CA2598517A1 (https=)
DK (1) DK1853241T3 (https=)
ES (1) ES2374761T3 (https=)
GB (1) GB0504103D0 (https=)
IL (1) IL185410A0 (https=)
MX (1) MX2007010480A (https=)
PT (1) PT1853241E (https=)
RU (1) RU2420272C2 (https=)
WO (1) WO2006090177A1 (https=)
ZA (1) ZA200707486B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2010054273A1 (en) * 2008-11-06 2010-05-14 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders
RS54632B1 (sr) 2011-06-23 2016-08-31 Swedish Orphan Biovitrum International Ab Tečna farmaceutska kompozicija koja sadrži nitizinon
CN103622942A (zh) * 2013-11-04 2014-03-12 江苏大学 左旋多巴/卡比多巴复方缓释混悬剂及其制备方法
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
ITUB20160650A1 (it) 2016-02-11 2017-08-11 Dipharma S A Formulazioni farmaceutiche solide stabili contenenti 2-(2-nitro-4-trifluorometilbenzoil)-1,3-cicloesandione
US9783485B1 (en) 2016-11-30 2017-10-10 Dipharma S.A. Crystalline inhibitor of 4-hydroxyphenylpyruvate dioxygenase, and a process of synthesis and crystallization thereof
TW202543611A (zh) * 2024-03-27 2025-11-16 美商費斯製藥有限公司 Ｈｐｄ抑制劑組成物及使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4780127A (en) * 1982-03-25 1988-10-25 Stauffer Chemical Company Certain 2-(substituted benzoyl)-1,3-cyclohexanediones and their use as herbicides
US5092919A (en) * 1991-01-15 1992-03-03 Imperial Chemical Industries Plc Certain 2-(2'-methyl-3',4'-trisubstituted benzoyl)-1,3-cyclohexanediones
JP3130935B2 (ja) * 1991-06-24 2001-01-31 ゼネカ リミテッド 医薬組成物
FR2777781B1 (fr) * 1998-04-24 2004-04-09 Rhone Poulenc Rorer Sa Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
US20050288187A1 (en) * 2002-07-03 2005-12-29 Hanauske-Abel Hartmut M Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases
WO2005007096A2 (en) * 2003-07-11 2005-01-27 Merck & Co., Inc. Treatment of movement disorders with a metabotropic glutamate 4 receptor positive allosteric modulator
NZ574153A (en) * 2006-08-18 2011-12-22 Syngenta Ltd Use of hppd inhibitors in the treatment of depression and/or withdrawal symptoms associated with addictive drugs
WO2010054273A1 (en) * 2008-11-06 2010-05-14 Synosia Therapeutics Treatment of restless leg syndrome and sleep disorders

Also Published As

Publication number Publication date
CN101163466A (zh) 2008-04-16
PT1853241E (pt) 2012-01-11
DK1853241T3 (da) 2012-01-16
RU2420272C2 (ru) 2011-06-10
HK1110211A1 (en) 2008-07-11
AU2006217650A1 (en) 2006-08-31
AU2006217650B2 (en) 2011-06-09
ES2374761T3 (es) 2012-02-21
CA2598517A1 (en) 2006-08-31
ZA200707486B (en) 2009-02-25
IL185410A0 (en) 2008-08-07
MX2007010480A (es) 2008-02-07
RU2007131934A (ru) 2009-02-27
JP2008531665A (ja) 2008-08-14
US20090326072A1 (en) 2009-12-31
ATE524171T1 (de) 2011-09-15
EP1853241A1 (en) 2007-11-14
WO2006090177A1 (en) 2006-08-31
BRPI0609177A2 (pt) 2010-02-23
EP1853241B1 (en) 2011-09-14
CN101163466B (zh) 2011-12-07

Similar Documents

Publication Publication Date Title
IL185410A0 (en) Use of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione in the treatment of parkinson's disease
MX2009006742A (es) Inhibidores acilaminopirazoles como fgfr.
PL1696905T3 (pl) Zastosowanie podstawionych 2-aminotetralin do zapobiegawczego leczenia choroby parkinsona
PT2527315E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
TW200728307A (en) Novel spirochromanone derivatives
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
TW200734311A (en) New compounds
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
EP1940373B8 (en) 1-fluoro-1-deoxy-scyllo-inositol for the treatment of alzheimer's disease
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
WO2009067493A3 (en) 1,3,5 tri-subtituted benzenes for treatment of alzheimer's disease and other disorders
DK1670903T3 (da) Behandling af neurodegenerative sygdomme
WO2010077068A3 (en) Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same
PT1778837E (pt) Tratamento de doenças neurodegenerativas por utilização de inibidores de scd4
TW200716547A (en) Piperidin-4-yl-amide derivatives
TW200639156A (en) New compounds
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
DE602006010738D1 (de) Pyrroloä2,3-cüpyridinderivate
TW200635595A (en) Medicaments for the treatment of prevention of fibrotic diseases
MX2009005351A (es) Compuestos utiles para tratar trastornos neurodegenerativos.
WO2007017511A3 (de) Verbindungen zur behandlung der alzheimer erkrankung
ZA200700945B (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2008057599A3 (en) Methods for the treatment of abeta related disorders and compositions therefor
WO2006080043A3 (en) Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)